Breast Cancer Resources
The Utah Breast & Cervical Cancer Screening Program provides cancer screenings to Utah women who are low income and uninsured, or underinsured. We serve:
- Women aged 40 and older for breast cancer screening
- Women aged 21-64 for cervical cancer screening
Free screenings may include:
- Mammogram
- Pap test
- Blood pressure
- Cholesterol
- Blood sugar
Guidelines and Legislation
Federal guidelines
The Utah Breast & Cervical Cancer Screening Program is funded by a grant from the CDC’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP).Learn more about the NBCCEDP on the CDC website.
Visit the U.S. Preventive Services Task Force (USPSTF) website for breast cancer screening recommendations.
Learn more about early detection and diagnosis from American Cancer Society’s website.
To improve access to cancer screening, Congress passed the Breast and Cervical Cancer Mortality Prevention Act of 1990.
Utah Breast & Cervical Cancer Program
The Breast & Cervical Cancer Screening Program contracts with surgeons, obstetricians, gynecologists, and gynecologic oncologists for reimbursement for specified diagnostic and follow-up procedures for clients who qualify for our program.
The program also contracts with various types of facilities.
If your office would like to work with our program, please call 1-800-717-1811
Providers are reimbursed at Medicare rates. We are unable to pay for treatment.
The B&C Program has approved the inclusion of self-collection HPV testing for cervical cancer screening. This update utilizes the current CPT codes for HPV testing. It’s important to note the following key points:
- HPV self-collection is for women ages 25-65 for primary HPV screening.
- HPV self-collection must be completed in a clinic under the supervision of a provider.
- Clinician-collected primary HPV testing is preferred over co-testing.
- Currently, only the BD Onclarity and Roche Cobas test kits are FDA-approved for self-collection, and no other kits should be used for this purpose.
- HPV self-collection is not recommended for individuals at high risk or for surveillance following specific diagnoses.
- When self-collected vaginal specimens are HPV-negative in the screening setting, repeat testing in 3 years is recommended.
- When self-collected vaginal specimens are positive for HPV 16 and/or 18, direct referral for colposcopy with concurrent cytology collection is recommended.
- When self-collected vaginal specimen HPV test results are: a) positive for HPV (untyped), b) negative for HPV 16/18 and positive for HPV HR12 (other); or c) negative for HPV 16/18 and positive for HPV 45, 33/58, 31, 52, 35/39/68, 51 or combinations thereof, obtaining a clinician-collected cervical specimen for cytology or dual stain is recommended. Subsequent management of cytology or dual-stain results per management guidelines is recommended.
- When self-collected vaginal specimen HPV test results are positive for HPV types 56/59/66 and no other carcinogenic types, 1 year repeat testing is recommended. If HPV-positive for any HPV type at the 1-year follow-up, colposcopy is recommended.
- The Enduring Guidelines Committee recommends self-collection HPV testing every 3 years. In contrast, the draft guidelines from the U.S. Preventive Services Task Force (USPSTF) suggest self-collection HPV testing every 5 years. The final USPSTF recommendations have not yet been published.
Please refer to the ASCCP Guidelines for Self-Collected HPV Screening (Journal of Lower Genital Tract Disease) article for further details and exclusions to the new guidelines.